BRP-201

• UNSPSC Description:

  Brp-201 is considered as a promising therapeutic target for the next generation of anti-inflammatory drugs in the research of inflammatory diseases. It is a new, effective and selective inhibitor of mPGES-1 with an IC50 value of 0.42 μM.

• Target Antigen:

  PGE synthase

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/brp-201.html

• Solubility:

  10 mM in DMSO

• Smiles:

  S=C1OC(C2=CC=C3C(N=C(C(C4=CC=C(CC(C)C)C=C4)C)N3CC5=CC=CC=C5Cl)=C2)=NN1

• Molecular Weight:

  503.06

• References & Citations:

  [1]Ergül AG, et al. Novel potent benzimidazole-based microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from BRP-201 that also inhibit leukotriene C4 synthase. Eur J Med Chem. 2022 Mar 5;231:114167.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2227434-74-2